| Literature DB >> 29106617 |
Michal A Swiat1, Sofia Dashko1, Maxime den Ridder1, Melanie Wijsman1, John van der Oost2, Jean-Marc Daran1, Pascale Daran-Lapujade1.
Abstract
Cpf1 is a new class II family of CRISPR-Cas RNA-programmable endonucleases with unique features that make it a very attractive alternative or complement to Cas9 for genome engineering. Using constitutively expressed Cpf1 from Francisella novicida, the present study demonstrates that FnCpf1 can mediate RNA-guided DNA cleavage at targeted genomic loci in the popular model and industrial yeast Saccharomyces cerevisiae. FnCpf1 very efficiently and precisely promoted repair DNA recombination with efficiencies up to 100%. Furthermore, FnCpf1 was shown to introduce point mutations with high fidelity. While editing multiple loci with Cas9 is hampered by the need for multiple or complex expression constructs, processing itself a customized CRISPR array FnCpf1 was able to edit four genes simultaneously in yeast with a 100% efficiency. A remarkable observation was the unexpected, strong preference of FnCpf1 to cleave DNA at target sites harbouring 5'-TTTV-3' PAM sequences, a motif reported to be favoured by Cpf1 homologs of Acidaminococcus and Lachnospiraceae. The present study supplies several experimentally tested guidelines for crRNA design, as well as plasmids for FnCpf1 expression and easy construction of crRNA expression cassettes in S. cerevisiae. FnCpf1 proves to be a powerful addition to S. cerevisiae CRISPR toolbox.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29106617 PMCID: PMC5716609 DOI: 10.1093/nar/gkx1007
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Figure 1.Schematic representation of DNA interference by the Cas9 and Cpf1 endonucleases. As compared to Cas9, Cpf1 does not require a tracrRNA, has a T-rich PAM sequence located at the 5′ end of the protospacer, is capable to mature its own crRNA array, cleaves DNA distal from the PAM and generates staggered ends.
List of yeast strains used in this study
| Strain name | Genotype | Origin |
|---|---|---|
| CEN.PK113–7D | MAT | ( |
| CEN.PK113–5D | MAT | ( |
| IMX1139 | MAT | This study |
| IME384 | MAT | This study |
| IME385 | MAT | This study |
| IMX1511 | MAT | This study |
| IMX1512 | MAT | This study |
| IMX1522 | MAT | This study |
| IMX1523 | MAT | This study |
| IMX1524 | MAT | This study |
| IMX1525 | MAT | This study |
| IMX1526 | MAT | This study |
| IMX1535 | MAT | This study |
List of plasmids used in this study
| Plasmid | Genotypea | Assemby method | Reference |
|---|---|---|---|
| p414- |
| ( | |
| pMEL10 | 2 μm ampR | ( | |
| pROS13 | 2 μm ampR KanMX | ( | |
| pRS416 |
| ( | |
| PY004 | ampR | ( | |
| pUDC175 (Addgene #103019) |
|
| This study |
| pUD520 | KanR |
| This study |
| pUD521 | KanR |
| This study |
| pUD438 | KanR |
| This study |
| pUD522 | KanR |
| This study |
| pUD523 | KanR |
| This study |
| pUD524 | KanR |
| This study |
| pUD550 | KanR |
| This study |
| pUD439 | KanR |
| This study |
| pUD440 | KanR |
| This study |
| pUD552 | KanR |
| This study |
| pUD605 | 2 μm KanMX ampR |
| This study |
| pUD606 | 2 μm KanMX ampR |
| This study |
| pUD627 | 2 μm KanMX ampR |
| This study |
| pUD607 | 2 μm KanMX ampR |
| This study |
| pUD608 | 2 μm KanMX ampR |
| This study |
| pUD609 | 2 μm KanMX ampR |
| This study |
| pUD628 (Addgene #103018) | 2 μm KanMX ampR |
| This study |
| pUD629 | 2 μm KanMX ampR |
| This study |
| pUD630 | 2 μm KanMX ampR |
| This study |
| pUDE712 | 2 μm KanMX ampR |
| This study |
| pUDE713 | 2 μm KanMX ampR |
| This study |
| pUDE714 (Addgene #103021) | 2 μm KanMX ampR |
| This study |
| pUDE708 | 2 μm KanMX ampR |
| This study |
| pUDE709 | 2 μm KanMX ampR |
| This study |
| pUDE710 (Addgene #103020) | 2 μm KanMX ampR |
| This study |
| pUDE720 | 2 μm KanMX ampR |
| This study |
| pUDE721 | 2 μm KanMX ampR |
| This study |
| pUDE722 (Addgene #103022) | 2 μm KanMX ampR |
| This study |
| pUDE723 | 2 μm KanMX ampR |
| This study |
| pUDE724 (Addgene #103023) | 2 μm KanMX ampR |
| This study |
| pUDE725 | 2 μm KanMX ampR |
| This study |
| pUDE735 (Addgene #103024) | 2 μm KanMX ampR |
| This study |
| pUD706 | 2 μm ampR |
| This study |
| pUDE731 (Addgene #103008) | 2 μm ampR |
| This study |
aThe presence of an S or a L following the crRNA name indicates that the direct repeats in the CRISPR array are either Short (19 nt) or Long (36 nt), respectively.
The reference number of plasmids deposited to Addgene is indicated next to the plasmid name between brackets when relevant.
Figure 7.Multiplex genome editing by FnCpf1 in S. cerevisiae. (A) composition of CRISPR arrays for single deletion of CAN1 and PDR12, and quadruple deletion of ADE2, CAN1, HIS4, and PDR12. Three different crRNAs were tested for CAN1 and PDR12. 19-nt direct repeats were used and CRISPR plasmids were assembled in vitro using Gibson assembly. (B) Fraction of transformants with single deletion using single arrays (plasmids used: pUDE720 to pUDE725). (C) Fraction of clones with triple (3D) and quadruple deletion (4D) after transformation with the quadruple array (pUDE735). No transformants without deletion, or with single or double deletion were found. Two strains were tested for multiplex genome editing, IMX1139 with genomic integration of Fncpf1 and IME384 in which Fncpf1 is carried by a multicopy plasmid. B, C: deletion was quantified by diagnostic PCR (Supplementary Figure S6). The number of transformants checked by PCR is indicated between brackets. Plating was performed just after transformation, without additional incubation.
Figure 2.Specific growth rate of strains expressing FnCpf1 and their control strains. A: IMX1139, expressing FnCpf1 constitutively from its genomic DNA, and its congenic control strain CEN.PK113–7D. B: IME384, expressing FnCpf1 from a multicopy plasmid (pUDE731) and its congenic control strain IME385 containing the same multicopy plasmid but without FnCpf1 (pUD706). The strains were cultivated in shake-flask on chemically defined medium with glucose as sole carbon source. The data points represent the average and mean deviation of two independent culture replicates.
Figure 3.Efficiency of ADE2 editing by FnCpf1. (A) Design of the CRISPR plasmid harbouring the CRISPR array for in vivo assembly in yeast. SHR, homologous sequence for recombination (43). (B) AT content and position in the coding region of ADE2 of the crRNAs. (C) Comparison of the genome editing efficiency of six crRNA with various AT content and target sequence (grey bars). The genome editing efficiency was also measured when cells were incubated after transformation in liquid medium for 48 h (black bars). The efficiency is calculated as the number of red colonies divided by the total number of colonies on the transformation plates in the presence of repair DNA fragments. Values represent the average and standard deviation of two biological and two technical replicates. (Plasmids used: pUD605 to pUD609, Table 2).
Attributes of the spacers used in this study
| Targeted gene | crRNA name | 5′ to 3′ sequence | AT content (%) | Position from ATG |
|---|---|---|---|---|
|
| crADE2–1 | T | 36 | 1438 |
| crADE2–2 | T | 44 | 723 | |
| crADE2–3 | T | 52 | 743 | |
| crADE2–4 | T | 60 | 1498 | |
| crADE2–5 | T | 72 | 247 | |
| crADE2–6 | T | 84 | 317 | |
|
| crCAN1–1 | T | 64 | 1204 |
| crCAN1–2 | CTT | 64 | 322 | |
| crCAN1–3 | CAT | 60 | 893 | |
| crCAN1–4 | GTT | 60 | 1123 | |
|
| crHIS4–1 | G | 56 | 1514 |
| crHIS4–2 | T | 72 | 328 | |
| crHIS4–3 | T | 52 | 730 | |
| crHIS4–4 | T | 52 | 227 | |
|
| crPDR12–1 | A | 64 | 1847 |
| crPDR12–2 | CAT | 52 | 39 | |
| crPDR12–3 | GTT | 60 | 2674 | |
| crPDR12–4 | CAT | 62 | 2269 |
NB: in the text and in Table 2, a letter is added at the end of the crRNA name listed in this table to indicate whether the crRNA is framed by short (S, 19 nt) or long (L, 36 nt) direct repeats.
ADE2 editing efficiency of FnCpf1 for interruption and point mutation using long (36 nt) and short (19 nt) direct repeats
| Protospacer | DR length | Mutation type | Plasmid assemblya | Genome editing efficiency |
|---|---|---|---|---|
| crADE2–3 (52% AT) | 36 nt | Deletion |
| 37 ± 2%b |
| 36 nt | Deletion | Pre-assembled | 19 ± 6%b | |
| 19 nt | Deletion | Pre-assembled | 100%2 | |
| 19 nt | Point mutation | Pre-assembled | 100%c |
aPre-assembled plasmids were purified from yeast cells after in vivo assembly and re-used for transformation to yeast.
b Efficiency calculated as the number of red colonies divided by the total number of colonies on the transformation plates in the presence of repair DNA fragments. Values represent the average and standard deviation of two biological and two technical replicates.
c Efficiency calculated by dividing the number of colonies with the correct point mutation over the total number of colonies tested.
Figure 4.Confirmation of FnCpf1-mediated introduction of a point mutation in ADE2. Sanger sequencing of the genomic DNA locus targeted for FnCpf1-mediated point mutation in seven randomly selected transformants. The control is the genomic DNA of the congenic strain CEN.PK113–7D. (Plasmid used: pUD628 carrying crADE2–3.S, Table 2).
Figure 5.FnCpf1-mediated editing of single and double genomic targets. (A) Composition of CRISPR arrays for single and double deletion of ADE2 and HIS4. 19-nt direct repeats were used and CRISPR plasmids were assembled in vitro using Gibson assembly. (B) Fraction of transformants with single or double deletion as measured by diagnostic PCR (Supplementary Figure S5), following the design described in A. The number of transformants checked by PCR is indicated between brackets. (Plasmids used: pUD628, pUDE712 to pUDE714, pUDE708 to pUDE710). Plating was performed just after transformation, without additional incubation.
Figure 6.Overview of PAM sequences of the crRNAs used in this study and their efficiency for genome editing. Only crADE2–6, which had an extreme AT content (84%) is not represented. Efficiency calculated as indicated in Figures 3 and 5. * indicates arrays containing 19-nt repeats instead of 36.